<DOC>
	<DOCNO>NCT02146703</DOCNO>
	<brief_summary>This study conduct phase II study gemcitabine S-1 first-line chemotherapy patient advance biliary tract cancer</brief_summary>
	<brief_title>Gemcitabine S-1 Advanced Biliary Tract Cancer</brief_title>
	<detailed_description>Biliary-tract cancer ( BTC ) invasive carcinoma originate epithelial line gallbladder bile duct . BTC include cholangiocarcinoma ( intrahepatic , perihilar , distal biliary-tree tumor ) carcinoma arise gallbladder . Surgical resection primary tumor potentially curative BTC , less quarter patient eligible resection presentation . Systemic chemotherapy principal treatment method patient unresectable metastatic BTC . Gemcitabine promising agent , show efficacy biliary tract cancer . As single-agent therapy , gemcitabine show response rate 8-36 % BTC [ 4 ] . In phase II trials patient advanced BTC , gemcitabine combination capecitabine platinum analogue produce objective response rate 26-50 % . The ABC-02 study report significant survival advantage gemcitabine cisplatin gemcitabine alone patient advanced BTC ( median overall survival 11.7 vs. 8.1 month ; P &lt; 0.001 ) . Oral anticancer drug S-1 consist 5-FU prodrug tegafur two biochemical modulators , 5-chloro-2,4-dihydroxypyridine ( CDHP ) potassium oxonate ( Oxo ) . S-1 monotherapy active advanced BTC objective response rate 21-35 % , phase II trial S-1 combination gemcitabine report objective response rate 20-36 % . Differences trial dos administration schedule gemcitabine S-1 may reflect range efficacy , dose-intensity , rate toxicity observe . Even though efficacy gemcitabine S-1 combination evident patient advance BTC previous phase II trial , clinical study investigate efficacy gemcitabine S-1 combination patient advance BTC study start . Therefore , conduct phase II study evaluate gemcitabine S-1 combination first-line chemotherapy patient advance BTC .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Unresectable , locally advanced , metastatic adenocarcinoma arise intra extrahepatic biliary duct gallbladder Initially diagnose recur At least one bidimensionally measurable lesion , define least 1x1cm clearly defined margin physical examination , 3dimentional CT , MRI , PETCT Age ≥18 ≤70 year Estimated life expectancy ≥3 month ECOG performance status ≤2 Adequate bone marrow function ( WBCs ≥4,000/µL absolute neutrophil count ≥1,500/µL , platelets ≥100,000/µL ) , Adequate kidney function ( creatinine ≤1.4 mg/dL ) Adequate liver function ( bilirubin ≤1.8 mg/dL , transaminase level ≤100mg/dL ) Written inform consent Other tumor type adenocarcinoma Previous history chemotherapy ( exception : adjuvant chemotherapy ) Presence CNS metastasis , psychosis , seizure Obvious bowel obstruction Evidence serious gastrointestinal bleeding Past concurrent history neoplasm biliary adenocarcinoma , except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri Pregnant lactate woman , woman childbearing potential employ adequate contraception Other serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>biliary tract neoplasm</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>S-1</keyword>
</DOC>